O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands
Verboom, D M; Varkila, M R J; Morrow, B; Davies, T; Ibarra de Palacios, P; Poolman, J; Hermans, P W M; Dudley, E G; Roberts, E; Cremer, O L; Bonten, M J M
(2021) Vaccine, volume 39, issue 12, pp. 1670 - 1674
(Article)
Abstract
OBJECTIVES: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. METHODS: We studied E.
... read more
coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. RESULTS: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). CONCLUSIONS: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.
show less
Download/Full Text
Keywords: Bloodstream infections, Escherichia coli, ExPEC, ICU, Vaccine, General Veterinary, Public Health, Environmental and Occupational Health, Infectious Diseases, Molecular Medicine, General Immunology and Microbiology, Journal Article
ISSN: 0264-410X
Publisher: Elsevier BV
Note: Funding Information: D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution (COMBACTE-CARE, grant agreement 115 620). Funding Information: We thank the members of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) consortium for their contribution to this research. D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union's Seventh Framework Programme (FP7/2007?2013) and EFPIA companies? in-kind contribution (COMBACTE-CARE, grant agreement 115 620). Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
(Peer reviewed)